DATATRAK Attains New Internal Records for Global EDC Implementations

DATATRAK Attains New Internal Records for Global EDC Implementations

New Highs Achieved in Three Categories - Monthly Data Items in November of Greater Than 450,000; Active Users at More Than 7,100 and Country Experience Base Reaches 47

CLEVELAND, Dec. 3 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (NASDAQ:DATA), the leading and most experienced Application Service Provider ("ASP") in the Electronic Data Capture ("EDC") industry today announced it has achieved new records in global EDC implementations. These new internal records are from three categories that are constantly tracked by the Company. The categories include data items entered by investigative staff around the world, the number of active users and the number of countries that have utilized the product suite.

Recently, DATATRAK has added two users who are clinical research associates based in Sofia, Bulgaria as one of the new geographic extensions of the Company's product influence. DATATRAK has also added contract users in India as the second new country location. These quantitative metrics are indicators of the continued growth of the EDC market and further emphasize that technology is increasingly being utilized in clinical trials on a global basis.

"Whenever appropriate we like to provide the markets with as many barometers as possible in which to gauge increasing adoption rates of EDC," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "These statistics from us and other facts from several of our competitors are consistent in verifying that technology is increasingly seen as the future in clinical trials compared to slower and more expensive manual methods of data collection and review. EDC is still in its infancy compared to the number of clinical trials that are performed with paper. As such, these indicators signify both excitement and challenges because there are years of growth ahead of this market sector which is viewed as inevitable by almost everyone associated with clinical trials. It is important to appreciate that our statistics are related only to the use of EDC and they do not include other applications such as clinical data management systems, patient diary applications or interactive voice response systems."

About DATATRAK International

DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(R) and related services to the pharmaceutical, biotechnology, and medical device industries. DATATRAK EDC(R) was developed in order to deliver clinical research data from investigative sites to clinical trial sponsors faster and more efficiently than conventional, manual methods. DATATRAK EDC(R) can be deployed worldwide in either a distributed platform using laptop computers or in a centralized environment using the Internet. DATATRAK EDC(R) software and its earlier versions have successfully supported many international clinical studies involving thousands of clinical research sites and encompassing tens of thousands of patients in over 40 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 14 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bonn, Germany. Its common stock is listed on the Nasdaq Stock Market under the symbol "DATA." Visit the DATATRAK International, Inc. web site at http://www.datatrak.net/ or http://www.datatraknet.de/ .

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward- looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK EDCÔ software; the development and fluctuations in the market for EDC technology; continued unreliability of the Internet infrastructure; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; dependence on key personnel; governmental regulation; the early stage of the Company's EDC business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.


Source: DATATRAK International, Inc.

CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief Executive
Officer, +1-440-443-0082 x112, or Terry C. Black, Chief Financial Officer,
+1-440-443-0082 x110, both of DATATRAK International, Inc.; or Neal Feagans,
Investor Relations of Feagans Consulting, Inc., +1-303-449-1184

Web site: http://www.datatraknet.de/
http://www.datatraknet.com/


-------
Profile: intent